RomânăFără categorie
Complete guide to BI-RADS (1-6) in mammography: what each category means and what comes after the result
You got your mammogram results and the sheet says “BI-RADS 4B” or “BI-RADS 3 — 6-month follow-up recommended.” Your heart stopped for a second. You immediately opened Google and started searching. If you recognize yourself in this situation, rest assured that you’re not alone — millions of women around the world go through the same moment of confusion and anxiety every year.
System ( BI-RADS ) is an internationally standardized language created by the American College of Radiology (ACR) that allows radiologists to communicate with each other and with their treating physicians in a consistent and accurate way. It has 7 categories (0 to 6), each with a well-defined risk of malignancy and a clear management recommendation. Once you understand what each category means, you will be able to have a much calmer and more informed conversation with your doctor.
What is the BI-RADS system and why was it created?
Before the advent of BI-RADS, each radiologist described mammography in their own way, which led to confusion and inconsistent decisions. The standardization brought by BI-RADS transformed mammography reporting: today, a BI-RADS category means the same thing whether you are examined in Bucharest, Paris or New York.
Important Update 2026 : The American College of Radiology released BI-RADS v2025 — the first major revision in 12 years (since 2013) — on December 1, 2025, at the RSNA conference. It officially integrates 3D mammography (digital tomosynthesis — DBT), contrast-enhanced mammography (CEM), and new Artificial Intelligence algorithms into the reporting standards.
BI-RADS 0 — Investigation Incomplete: Does not mean cancer, means more information is needed
Risk of malignancy : Cannot be determined — investigation not completed.
Category 0 means that the radiologist cannot make a final verdict based on the images available at that time. Starting with BI-RADS v2026, this category is now explicitly separated into two distinct situations — a major innovation over previous versions:
- Situation A : Additional imaging — spot compression, mammography in another incidence, ultrasound, or MRI — is needed before a conclusion can be reached.
- Situation B : The examination might be interpretable, but the doctor needs to see previous mammograms from another institution for comparison.
This clarification is essential because previously, both situations generated the same anxiety: patients believed they had to return urgently for additional imaging, when in fact the doctor only wanted to compare with an old exam.
What’s next : An appointment for further investigations or bringing in previous mammograms. In modern programs with 3D tomosynthesis (DBT), call rates for further investigations have decreased by 15–30% compared to classic 2D mammography.
BI-RADS 1 — Normal Mammography (Negative)
Risk of malignancy : ~0%.
The best news: no abnormalities detected. The breasts are symmetrical, there are no masses, architectural distortions or suspicious calcifications.
What’s next : Routine screening, age-appropriate.
- Women at average risk: annual mammography starting at age 40 (according to ACR/NCCN)
- Women at high risk (BRCA1/2 mutations, strong family history): annual mammography plus annual breast MRI, starting at age 25–30
- Dense breasts (categories C or D): additional imaging (ultrasound, MRI, or CEM) is recommended
New in 2026 : The AI Clairity Breast platform , cleared by the FDA in 2026, can analyze an apparently normal mammogram (BI-RADS 1) and calculate a risk score for the next 5 years — identifying women who appear healthy but would benefit from more intensive screening.
BI-RADS 2 — Benign Lesion (Definitely Benign)
Risk of malignancy : Practically 0%.
The radiologist has detected something, but it is definitely benign —there is no suspicion of cancer. The doctor documents the findings for possible future comparisons.
Typical examples of BI-RADS 2 lesions:
- Simple cysts on ultrasound
- Calcified fibroadenomas
- Normal intramammary lymph nodes
- Lipoma, hamartoma
- Vascular calcifications, “popcorn” calcifications (benign)
- Stable post-surgical scar
What’s next : No further investigation or intervention required. Routine screening continues.
BI-RADS 3 — Probably Benign: 6 Month Follow-up
Risk of malignancy : ≥0% and <2%.
This category perhaps generates the most stress, because it says neither “everything is fine” nor “a biopsy is needed.” It means that the doctor has seen a change with a very high probability of being benign , but wants to confirm its stability over time.
Types of lesions that fall into BI-RADS 3:
- A solid, oval, well-demarcated, painless mass discovered for the first time
- A focal asymmetry that partially attenuates upon compression
- A cluster of round or point-shaped calcifications on a basic exam
Standard tracking protocol :
- At 6 months : Repeat mammogram on the same side
- At 12 months : Bilateral mammography
- At 24 months : Bilateral mammography
- If stable at 24 months : Reclassification to BI-RADS 2 — the lesion is considered benign
- If any change occurs at any interval : Reclassification to BI-RADS 4 → biopsy
Biopsy is acceptable as an alternative if the patient has severe anxiety, difficulty accessing follow-up, or there is a pregnancy.
BI-RADS 4 — Suspicious: Biopsy Recommended
Risk of malignancy : >2% and <95%.
This is the category that usually sends the patient for a biopsy. It does not automatically mean it is cancer — it means that the lesion does not have the clear characteristics of a benign or malignant lesion. The spectrum is broad, so BI-RADS 4 is divided into three subcategories :
| SUB | Description | Risk of malignancy |
| 4A | Low suspicion | 2%–10% |
| 4B | Intermediate suspicion | 10%–50% |
| 4C | Moderate suspicion (but not definite) | 50%–95% |
Practical examples :
- 4A : A partially circumscribed, palpable solid mass; amorphous calcifications
- 4B : Mass with indistinct borders; mixed mass (solid and cystic) with internal contents
- 4C : Mass with spiculated edges without all criteria for BI-RADS 5; fine pleomorphic calcifications
What’s next : Image-guided biopsy — the standard is core needle biopsy (CNB) , generally under ultrasound or stereotactic (mammographic) guidance. New 2026 : DBT (3D tomosynthesis) guided biopsy is now preferred over classic 2D guidance, as it involves less radiation and shorter procedure time.
BI-RADS 5 — Highly Suggestive of Malignancy: Biopsy Mandatory
Risk of malignancy : ≥95%.
The images have the classic features of breast cancer . Biopsy is mandatory for histological confirmation before any treatment.
Typical BI-RADS 5 features:
- Irregular mass with spiculated edges and high density
- Fine linear or branched calcifications, distributed segmentally
- New architectural distortion without surgical history
Complete workup after confirmation :
- Biopsy with mandatory placement of a metal clip (marker) at the biopsy site — essential for surgical planning
- Axillary ultrasound with biopsy of suspicious lymph nodes
- Breast MRI to assess disease extension
- Complete molecular profile (ER/PR, HER2, Ki-67) — dictates the entire therapeutic plan
- BRCA1/BRCA2 genetic testing — recommended for all newly diagnosed patients (NCCN v5.2026)
- Staging imaging (chest/abdominal CT, PET/CT) in locally advanced disease
BI-RADS 6 — Malignancy Confirmed by Previous Biopsy
Risk of malignancy : Confirmed — 100% (by previous biopsy).
This category is used when the patient already has a histologically confirmed diagnosis of breast cancer and is undergoing imaging for treatment planning, monitoring response to neoadjuvant chemotherapy, or preparation for surgery.
New in BI-RADS v2026 : A specific guidance section has been added for the management of Category 6 on MRI — including how to assess response to neoadjuvant chemotherapy and how to interpret imaging in the context of active treatment.
What’s New in 2026: Game-Changing Technologies
Digital Tomosynthesis (DBT — 3D Mammography) : Now fully integrated into BI-RADS v2026, DBT significantly reduces call rates for additional investigations and improves detection of invasive cancers, including lobular cancers (difficult to see on classic mammography).
Contrast-enhanced mammography (CEM) : Elevated to core modality status in BI-RADS v2026 (no longer a simple ancillary method). Provides functional information comparable to MRI, at a lower cost and without the need for an MRI appointment.
Artificial Intelligence : AI mammography analysis systems have been shown to perform better when paired with a single radiologist than two radiologists working without AI—reducing the rate of missed cancers and false positives.
📊 BI-RADS GUIDE FOR PATIENTS
What your mammogram result means — simply explained, without complicated medical terms
TABLE 1: WHAT BI-RADS CATEGORY MEANS — Explained as if to a friend
| CATEGORY | WHAT IS IT NAMED? | ON YOUR OWN WAY | HOW WORRIED SHOULD YOU BE? | WHAT ARE YOU DOING NOW? |
| 0 | ⚠️ Investigation not completed | The radiologist can’t give a definitive answer with the images he has. It doesn’t mean there’s anything wrong — it just means he needs more information. | 😐 Neutral — don’t panic | 🔄 Either go for an additional investigation (ultrasound, other pictures), or bring old mammograms from another hospital for comparison |
| 1 | ✅ Everything is normal | The breasts look perfectly healthy. No shadows, no masses, no suspicious calcifications. The best possible result. | 😊 No worries | 📅 Continue your annual routine check-up |
| 2 | ✅ Benign (harmless) change | The radiologist saw something, but it’s definitely harmless — a simple cyst, an old calcification, a normal lymph node. It’s not cancer and it won’t become cancer. | 😊 No worries | 📋 Note in the file for future comparisons. Continue routine control |
| 3 | 🟡 Most likely benign | There’s a small change, but the radiologist estimates there’s less than a 2% chance it’s cancer. He wants to track it over time, not act immediately. | 😌 Small concern — follow-up, not an emergency | 🕐 Come back for a check-up after 6 months , then 1 year , then 2 years . If it remains the same → confirmed benign ✅ |
| 4A | 🟠 Slightly suspicious | The change does not look 100% benign, but not 100% malignant either. The risk of cancer is between 2% and 10%. It is not an emergency, but it should be investigated. | 😟 Moderate worry | 🔬 Biopsy — a thin needle collects a few cells for analysis in the laboratory |
| 4B | 🟠 Moderately suspicious | The picture has some worrying features. The risk of cancer is between 10% and 50% — that is, “more than a one in 10 chance, but less than a one in two chance.” | 😟 Serious concern | 🔬 Mandatory biopsy — the biopsy result decides the next steps |
| 4C | 🔴 Quite suspicious | The change has several characteristics associated with cancer. The risk is between 50% and 95%. It is not certain, but the probability is high. | 😰 High concern | 🔬 Urgent biopsy — most likely it will be necessary to prepare a treatment plan |
| 5 | 🔴 Classic aspect of malignancy | The images show exactly what a cancer looks like on a mammogram. The probability is over 95%. A biopsy is mandatory to confirm and start treatment. | 😰 Very high concern | 🚨 Urgent biopsy + oncology consultations — the full medical team goes into action |
| 6 | ⬛ Cancer confirmed by previous biopsy | You already have a confirmed diagnosis from a previous biopsy. This category is used when you have imaging to plan treatment or to see if treatment is working. | 🏥 You are already in medical care | 🏥 You follow the treatment plan established by your oncology team |
TABLE 2: BIRADS 3 TRACKING PROTOCOL — Step by Step, in Your Understanding
💡 Remember : BI-RADS 3 means that the doctor wants to make sure that the change is stable over time — not that they suspect something serious. Statistically, 98 out of 100 BI-RADS 3 lesions turn out to be benign!
| WHEN? | WHAT ARE YOU DOING? | IF EVERYTHING IS THE SAME | IF A CHANGE OCCURS | WHAT DOES THIS MEAN? |
| Now (First detection) | You receive the BI-RADS 3 result | ➡️ Plan your check-up from 6 months | — | The change was observed and documented |
| After 6 months | Mammography/ultrasound of the affected breast | ➡️ Go for your 12-month checkup | ⬆️ Reclassification to BI-RADS 4 → Biopsy | If nothing has changed, that’s a good sign! |
| After 12 months | Mammography of both breasts | ➡️ Go for your 24-month checkup | ⬆️ Reclassification to BI-RADS 4 → Biopsy | Second checkpoint: stability confirmed |
| After 24 months | Mammography of both breasts | ✅ BI-RADS 2 — confirmed benign! | ⬆️ Reclassification to BI-RADS 4 → Biopsy | If it is stable for 2 years → with certainty benign |
| Anytime (Alternative) | You can choose the biopsy directly | — | — | If you have high anxiety, are pregnant, or cannot return regularly — biopsy is a valid option |
TABLE 3: BI-RADS 4 SUBCATEGORIES — What Each Means in Practice
💡 Important to know : BI-RADS 4 does not mean cancer — it means “worth further investigation.” Even in 4C, a third of cases turn out to be benign!
| SUBCATEGORY | CANCER RISK | HOW IT LOOKS ON A MAMMOGRAPHY | HOW IT LOOKS ON ULTRASOUND | WHAT IS SPECIFICALLY HAPPENING? |
| 4A — Low suspicion | 2% — 10% (about 1 in 10 maximum) | A mass with partially clear contours; calcifications in groups that appear normal | A solid table with almost clear edges | Core needle biopsy (painless, under local anesthesia, 15-20 minutes) |
| 4B — Medium suspicion | 10% — 50% (between 1 in 10 and 1 in 2) | Unclear margins of a mass; calcifications with mixed appearance | Table with mixed interior (part solid, part liquid) | Mandatory biopsy; histological result decides the next step |
| 4C — Higher suspicion | 50% — 95% (more than 1 in 2) | Irregular mass with stellate outlines; fine linear calcifications | Irregular, hard mass on elastography | Urgent coarse needle biopsy (BAB); most likely oncological consultations will follow |
TABLE 4: STEPS AFTER BI-RADS 5 — What Happens Step by Step
💡 Remember : Even if you received BI-RADS 5, the biopsy is the one that definitively confirms the diagnosis . Without a biopsy, there is no diagnosis!
| Step | WHAT AN INVESTIGATION | WHY IS IT NECESSARY? | WHO DOES IT? |
| 1 | 🔬 Thick needle biopsy + metal clip placement (microscopic — not felt) | Harvest cells for confirmation in the lab. The clip marks the spot for the surgeon. | Interventional radiologist |
| 2 | 🔊 Axillary (armpit) ultrasound | Check if the lymph nodes look normal or are affected | Radiologist |
| 3 | 🖼 ️ Mammography of both breasts | Also check the healthy breast + assess the exact extension of the lesion | Radiologist |
| 4 | 🧲 Bilateral breast MRI (optional) | Provides the most detailed image of both breasts — useful for seeing if there are other outbreaks | Radiologist |
| 5 | 🧬 Complete molecular profile (from the biopsy already collected) | the exact subtype of cancer → dictates which treatment works best | Anatomical pathologist |
| 6 | 🧪 BRCA1/BRCA2 genetic test (from blood) | Check for an inherited genetic mutation — important for your family too | Geneticist |
| 7 | 📊 Genomic test (optional) | Answers the question: “Does the patient need chemotherapy or not?” (e.g. Oncotype DX) | Specialized laboratory |
| 8 | 🏥 Tumor Board (Oncology Commission) | Doctors from several specialties (oncologist, surgeon, radiation therapist, radiologist) come together and together establish the best plan for you | Multidisciplinary medical team |
TABLE 5: WHAT TREATMENT COMES NEXT — Explained on Subtypes, on Your Understanding
💡 The most important message : Treatment is not determined only by where the cancer is, but especially by its “molecular type” — that is, what proteins it has on its surface. That’s why biopsy and molecular profiling are essential!
| CANCER TYPE (from biopsy) | WHAT DOES IT MEAN IN YOUR MEANING? | MAIN TREATMENT 2026 | GOOD NEWS |
| HR+ / HER2− (most common) | The cancer “feeds” on hormones (estrogen/progesterone). HER2 is negative (absent). | 💊 Hormonal pills (tamoxifen or aromatase inhibitors) for 5-10 years ± chemotherapy if genomic score recommends it | Responds excellently to hormonal treatment; chemotherapy is often not necessary |
| HER2+ (any HR) | There is a protein called HER2 in excess on the surface of the cells — this accelerates tumor growth | 💉 Monoclonal antibodies (trastuzumab + pertuzumab) + chemotherapy. Highly effective targeted treatment | Anti-HER2 targeted therapy has completely transformed the prognosis of this subtype |
| Triple-Negative (TNBC) | It has no hormone receptors or HER2. It is more aggressive, but responds well to modern treatments. | 💉 Immunotherapy (pembrolizumab) + chemotherapy. If you have a BRCA mutation → olaparib | Immunotherapy has revolutionized the treatment of TNBC in the last 3 years |
| HR+ / HER2-low | Similar to HR+, but with a small amount of HER2 protein (not enough for HER2+) | 💊 Hormone therapy + new drug T-DXd (Enhertu) in advanced disease | A new drug (T-DXd) has opened up completely new therapeutic options for this subtype |
TABLE 6: BREAST DENSITY — What It Means and Why It Matters
💡 Since 2024 (US law — FDA MQSA) , any mammography center is required to tell you what density your breasts have. In Romania, this information appears more and more frequently in reports.
| CATEGORY | WHAT SIMPLE MEANS | HOW WELL DOES MAMMOGRAPHY SEE? | DO YOU NEED FURTHER INVESTIGATION? |
| A — Almost entirely fat | The breasts contain little dense tissue — they look like an open landscape. Everything is clearly visible. | ~87% — Excellent | ✅ Standard mammography is sufficient |
| B — Density-dispersed areas | A few denser areas, but generally well visible | ~82% — Very good | ✅ Standard mammography is sufficient |
| C — Dense heterogeneous | Quite a lot of dense tissue — some small tumors can be “hidden” behind it, like a white spot on a white background | ~67% — Moderate | ⚠️ It is recommended additional ultrasound |
| D — Extremely dense | Breasts are very dense — mammography alone misses almost half of cancers | ~48% — Limited | 🔴 MRI or contrast mammography (CEM) mandatory |
TABLE 7: INVESTIGATION TECHNOLOGIES — Simple Comparison for Patients
| INQUIRY | Does it last? | Radiation? | Injection? | When is it recommended? |
| Classic 2D mammography | 10–15 minutes | Yes (small) | Not | Routine screening, average risk |
| 3D mammography (DBT) ⭐ Favorite 2026 | 15–20 minutes | Yes (slightly more) | Not | Preferred screening — sees better, fewer unnecessary recalls |
| Contrast-enhanced mammography (CEM) ⭐ Nine | 20–30 minutes | Yes | Yes (iodine, intravenously) | Dense breasts (C/D); alternative to MRI when unavailable |
| Breast ultrasound | 20–30 minutes | ❌ No radiation | Not | Additional to increased density; biopsy guidance; under 30 years old |
| Full breast MRI | 45–60 minutes | ❌ No radiation | Yes (gadolinium, intravenously) | BRCA carrier; disease extension; very high risk |
| Abbreviated MRI (AB-MRI) ⭐ New 2026 | 3–10 minutes | ❌ No radiation | Yes (gadolinium) | Faster and cheaper alternative to full MRI; intermediate risk |
TABLE 8: FREQUENTLY ASKED QUESTIONS FROM PATIENTS — Direct Answers
| YOUR QUESTION | THE HONEST ANSWER |
| “Does BI-RADS 3 mean I have cancer?” | No. It means there is a change with less than a 2% chance of being cancer. 98 out of 100 women with BI-RADS 3 do not have cancer. |
| “Does BI-RADS 4 mean I have cancer?” | Not necessarily. Even at 4C (the most worrisome subcategory), 1 in 3 biopsies are benign. The biopsy is definitive. |
| “Does BI-RADS 5 mean I have cancer?” | The probability is very high (over 95%) , but the official diagnosis is made ONLY after biopsy. Without histological confirmation, there is no diagnosis and there is no treatment. |
| “Can I wait with the biopsy?” | For BI-RADS 4 and 5 — No. Delaying biopsy may allow disease progression. For BI-RADS 3 — yes, follow-up is the standard option. |
| “Why do I need so many investigations after the biopsy?” | Each investigation answers a different question: the biopsy tells WHAT type of cancer, the molecular profile tells HOW to treat it, the imaging tells HOW far it has spread. |
| “Who decides my treatment?” | A committee (Tumor Board) made up of at least 4-5 doctors from different specialties — oncologist, surgeon, radiation therapist, radiologist, anatomopathologist. No doctor decides alone. |
| “Can I get a second opinion?” | Yes, and it is recommended! Especially for complex cases. The Oncoexpertai.com platform offers you a digital second opinion based on the international NCCN and ESMO guidelines. |
TABLE 9: FROM MAMMOGRAPHY TO TREATMENT — The Complete Map of Your Journey
| STAGE | WHAT’S HAPPENING | WHAT DO YOU FEEL? | HOW ONCOEXPERT AI HELPS YOU |
| 1. Screening | Do you have a routine mammogram or as recommended by your doctor? | 😐 A routine procedure | — |
| 2. You get the result | The BI-RADS report reaches you or your doctor | 😰 Confusion, fear, incomprehensible terms | 🤖 AI translates technical terms into plain language and explains what your category means |
| 3. Decision: What do you do now? | BI-RADS 1-3: follow-up / BI-RADS 4-5: biopsy | 😟 Anxiety about next steps | 🤖 AI checks whether the recommendation received complies with the international ACR and NCCN guidelines |
| 4. Biopsy | A thin needle harvests a few cells; takes 20-30 minutes under local anesthesia | 😬 Fear of procedure (worse in imagination than in reality) | 🤖 AI integrates biopsy results with imaging data |
| 5. Molecular profile | The laboratory tests markers ER, PR, HER2, Ki-67 — from the same biopsy | 😰 Waiting for the results (the hardest) | 🤖 AI correlates molecular profile with updated treatment guidelines |
| 6. Tumor Board | The multidisciplinary medical team establishes the treatment plan | 😟 A lot to process, a lot of questions | 🤖 AI works like a digital “pre-Tumor Board” — you arrive at the committee with all the data in order and the right questions |
| 7. Treatment | Surgery, chemotherapy, radiation therapy, hormone therapy, immunotherapy — or a combination | 🏥 Long but structured process | 🤖 AI tracks compliance with NCCN/ESMO protocols and alerts if relevant changes occur in the guidelines |
| 8. Monitoring | Periodic check-ups to detect any recurrence of the disease early | 😌 Hope, vigilance | 🤖 AI analyzes any new investigation in the context of your complete case history |
How Oncoexpert AI helps after receiving the mammogram result
A BI-RADS 4C or 5 result means a wave of investigations, decisions, and treatment protocols that can be overwhelming. The NCCN and ESMO international guidelines are constantly updated — in 2026, major changes were made regarding sentinel node biopsy, immunotherapy in triple-negative cancer, and genomic testing.
The Oncoexpert AI platform automatically correlates the BI-RADS category, biopsy histological profile, molecular markers (ER/PR/HER2/Ki-67) and staging with the latest international guidelines, giving you the certainty that the proposed therapeutic regimen is supported by the latest scientific evidence. The technology does not replace the doctor — it works as a digital “pre-Tumor Board” , helping you reach the medical commission with all the information at hand.
📂 Have you received a mammogram result and want to understand the full implications? Upload your medical file to Oncoexpertai.com and receive an informed second opinion, based on international NCCN and ESMO protocols, assisted by Artificial Intelligence.
Disclaimer: The information in this article is for informational and educational purposes only. It is not a medical document, does not replace the consultation of a specialist radiologist or oncologist, and does not constitute a diagnosis. The correct interpretation of any mammogram is made exclusively by the specialist doctor, in correlation with the entire clinical context and the patient’s personal history. Any therapeutic decision should be made together with your medical team.
Fișierul „MAMOGRAFIE EN.docx” este despre interpretarea rezultatelor de mamografie prin sistemul BI-RADS 0–6, screening mamar, densitate mamară, biopsie, DBT/3D mammography, CEM, RMN mamar și ghiduri NCCN/ESMO/ACR . Pentru acest conținut, poți folosi următoarele 7 surse bibliografice în stil Vancouver:
- American College of Radiology. ACR BI-RADS Atlas: Breast Imaging Reporting and Data System. 5th ed. Reston, VA: American College of Radiology; 2013.
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Screening and Diagnosis. Plymouth Meeting, PA: NCCN; latest version. Available from: https://www.nccn.org/guidelines
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Plymouth Meeting, PA: NCCN; latest version. Available from: https://www.nccn.org/guidelines
- Mann RM, Athanasiou A, Baltzer PAT, Camps-Herrero J, Clauser P, Fallenberg EM, et al. Breast cancer screening in women with extremely dense breasts: recommendations of the European Society of Breast Imaging — EUSOBI. European Radiology. 2022;32(6):4036–4045. doi:10.1007/s00330-022-08617-6.
- Friedewald SM, Rafferty EA, Rose SL, Durand MA, Plecha DM, Greenberg JS, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014;311(24):2499–2507. doi:10.1001/jama.2014.6095.
- Jochelson MS, Lobbes MBI. Contrast-enhanced mammography: state of the art. Radiology. 2021;299(1):36–48. doi:10.1148/radiol.2021201948.
- McKinney SM, Sieniek M, Godbole V, Godwin J, Antropova N, Ashrafian H, et al. International evaluation of an AI system for breast cancer screening. Nature. 2020;577(7788):89–94. doi:10.1038/s41586-019-1799-6.